- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05932420
Role of Intermittent Exogenous Ketosis in the Physiological and Muscular Adaptive Response to Endurance Training
Role of Intermittent Exogenous Ketosis in the Physiological and Muscular Adaptive Response to Endurance Training. A Study in Young, Male Volunteers.
In a recent study (Poffé et al., 2019), we demonstrated that increasing the concentration of ketone bodies in the blood through the ingestion of a ketone ester (KE) post-exercise and just before sleeping time during a 3-week overtraining period resulted in suppression of the physiological symptoms of overtraining. Consistent KE intake improved endurance performance, positively affected the autonomic regulation of the heart, suppressed the increase of nocturnal sympathetic activity, and increased spontaneous energy intake. In addition, KE intake had a positive effect on muscular adaptive response, as evidenced by the significantly increased muscular angiogenesis. Therefore, in this study, we aim to investigate whether the oral administration of ketones after exercise and just before bedtime also has a positive effect on the adaptive response during a well-dosed endurance training program. Since suppression of nocturnal sympathetic activity can positively influence sleep quality, we will also study the effect of KE and the training period on sleep quality.
To investigate this, we will use a randomized, placebo-controlled parallel research design. Well-trained male cyclists will participate in a fully controlled intervention period of 8 weeks. During the intervention period, participants will follow a supervised cycling training program (5-7 training sessions per week) with a gradual buildup aimed at improving endurance capacity.
Throughout the intervention period, participants will ingest 25g ketone ester or a corresponding placebo after each training session and 30 minutes before bedtime. Endurance performance will be evaluated before the start of the training period (pretest), after week 3 (midtest), after week 7 (posttest) of the training period, and at the end of the training intervention (posttest+taper). Additionally, blood samples will be taken at the pre-test and post-test to analyze markers of hormonal status and inflammation. Muscle biopsies will be taken from the vastus lateralis muscle of the right leg at pretest and posttest to analyze cross-sectional area, muscle fiber typing, angiogenesis, protein synthesis and degradation, mitochondrial function, and energy substrate concentrations. One month after the intervention period, an additional biopsy will be taken to study changes in gene expression (epigenetic modifications). Sleep will be evaluated via polysomnography (PSG) at the pretest, midtest and posttest. Finally, before and after the training period, resting and exercise echocardiography will be taken to investigate investigate structural and morphological changes of the heart.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Vlaams-Brabant
-
Leuven, Vlaams-Brabant, Belgium, 3000
- Exercise Physiology Research Group
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Physically fit and regularly involved in physical activity (2-5 exercise sessions of > 30min per week)
- Good health status confirmed by a medical screening
- VO2max higher than 50 ml.min-1.kg-1
- Body Mass Index (BMI) between 18 and 25
- Normal sleep pattern as assessed by the Pittsburgh Sleep Quality Index (PSQI, appendix 2)
Exclusion Criteria:
- Any kind of injury/pathology that is a contra-indication to perform high-intensity exercise
- Intake of any medication or nutritional supplement that is known to affect exercise performance or sleep
- Intake of analgesics, anti-inflammatory agents, or supplementary anti-oxidants, from 2 weeks prior to the start of the study.
- Night-shifts or travel across time zones in the month preceding the study
- Blood donation within 3 months prior to the start of the study
- Smoking
- More than 3 alcoholic beverages per day or more than one glass if wine per day
- Involvement in elite athletic training at a semi-professional or professional level
- Any other argument to believe that the subject is unlikely to successfully complete the full study protocol
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Placebo Comparator: Control group
Placebo is provided
|
16.4g pure medium triglyceride oil mixed with 1 mM of bitter sucrose octaacetate.
A dose of 25g of the placebo drink is provided immediately after each training session and 30 minutes before sleeptime throughout the training period.
|
|
Experimental: Experimental groep
Ketone ester is provided
|
A dose of 25g of ketone ester after each training session and 30 minutes before sleeptime throughout the training period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in mean power output during a 30min cycling time trial
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention) - Posttest+taper (after week 8 of the training intervention)
|
Change in mean power output during a self-paced 30 min cycling time trial on a cyling ergometer
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention) - Posttest+taper (after week 8 of the training intervention)
|
|
Change in capillarization of the musculus vastus lateralis
Time Frame: Pretest (before the start of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in capillarization (CFPE-index) of the musculus vastus lateralis
|
Pretest (before the start of the training intervention) - Posttest (after week 7 of the training intervention)
|
|
Change in sleep efficiency
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in sleep efficiency measured by polysomnography
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
|
Change in REM sleep
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in REM sleep measured by polysomnography
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in the nocturnal urinary excretion of dopamine
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in the nocturnal urinary excretion of dopamine
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
|
Change in the nocturnal urinary excretion of noradrenaline
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in the nocturnal urinary excretion of noradrenaline
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
|
Change in the nocturnal urinary excretion of adrenaline
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in the nocturnal urinary excretion of adrenaline
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
|
Change in maximal oxygen uptake
Time Frame: Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Change in maximal oxygen uptake measured during a maximal incremental exercise test on a cycling ergometer
|
Pretest (before the start of the training intervention) - Midtest (after week 3 of the training intervention) - Posttest (after week 7 of the training intervention)
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Poffe C, Ramaekers M, Van Thienen R, Hespel P. Ketone ester supplementation blunts overreaching symptoms during endurance training overload. J Physiol. 2019 Jun;597(12):3009-3027. doi: 10.1113/JP277831. Epub 2019 May 22.
- Robberechts R, Albouy G, Hespel P, Poffe C. Exogenous Ketosis Improves Sleep Efficiency and Counteracts the Decline in REM Sleep Following Strenuous Exercise. Med Sci Sports Exerc. 2023 Jun 1. doi: 10.1249/MSS.0000000000003231. Online ahead of print.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- S66150
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Exercise Adaptations
-
Biruni UniversityNot yet recruitingResistance Exercise | Adult | Muscle | Neuromuscular AdaptationsTurkey (Türkiye)
-
Centre Hospitalier de CorbieRecruitingExercise Training | Cardiac Rehabilitation | Exercise Intolerance | Exercise Intervention | Exercise Adaptations | HFrEF - Heart Failure With Reduced Ejection FractionFrance
-
Kastamonu UniversityCompletedAthletic Performance | Muscle Strength | Physical Fitness | Plyometric Exercise Adaptations | Neuromuscular Performance in AthletesTurkey (Türkiye)
-
Ali Kamil GÜNGÖRCompletedHemodynamic Changes | Neuromuscular Adaptations | Cardiac Autonomic Function | Exercise and RecoveryTurkey (Türkiye)
-
University of LausanneSociété des Produits Nestlé (SPN)CompletedHealthy Volunteers | Exercise Intensity | Neuromuscular Fatigue | Skeletal Muscle AdaptationsSwitzerland
-
University of MalagaCompleted
-
Gümüşhane UniversıtyCompletedAthletic Performance | Neuromuscular AdaptationsTurkey (Türkiye)
-
Federal University of Rio Grande do SulRecruitingAchilles Tendon Rupture | Neuromuscular Adaptations | Strength Training AdaptationsBrazil
-
University of MaiaNot yet recruitingRecovery | Strength Training Adaptations
-
Northeast College of Health SciencesNot yet recruitingAthletic Performance | Lower Limb | Neuromuscular Adaptations | Chiropractic ManipulationUnited States
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
AkesoNot yet recruitingAtopic DermatitisChina
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States